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Neutrophil-mediated skin diseases, originally named neutrophilic dermatoses (NDs),
are a group of conditions due to an altered neutrophil recruitment and activation,
characterized by polymorphic cutaneous manifestations with possible internal organ
involvement. Although a number of diseases are included in this setting, the two
prototypic forms are pyoderma gangrenosum (PG) and Sweet’s syndrome (SS) which
usually present with skin ulcers and plaque-type lesions, respectively. They have central
features significantly overlapping with autoinflammatory conditions which manifest
as repeated episodes of tissue inflammation. However, in contrast to appropriate
inflammatory responses to insults or to autoimmune disease, there is an absence of
identifiable pathogens, autoantibodies, or autoreactive lymphocytes. The recognition
of monogenic autoinflammatory diseases which can present with NDs has led to
study several genes involved in autoinflammation in NDs. Based on discovering of a
number of mutations involving different autoinflammatory genes, neutrophil-mediated
skin diseases are nowadays regarded as a spectrum of polygenic autoinflammatory
conditions. Although disease mechanisms have not yet been completely elucidated,
NDs are recognized as diseases involving dysfunctional cellular signaling mediated
by pathways mainly related to inflammasome and IL-1 with the contributory role of
IL-17 and other effector molecules. The precise elucidation of the above-mentioned
pathologic mechanisms may pave the way to tailored treatments for patients with
different neutrophil-mediated skin diseases.
Keywords: neutrophil-mediated skin diseases, autoinflammation, inflammasome, cytokines, pyoderma
gangrenosum
INTRODUCTION
Neutrophilic dermatoses (NDs) are a heterogenous subset of conditions with common features
and overlapping pathophysiology. They primarily present with cutaneous manifestations due
to accumulation of neutrophils but may affect additional tissues. The most well-defined
NDs include pyoderma gangrenosum (PG), Sweet’s syndrome (SS), subcorneal pustular
dermatosis, neutrophilic eccrine hidradenitis (NEH), bowel-associated dermatosis-arthritis
syndrome (BADAS), rheumatoid neutrophilic dermatitis, Behçet’s disease (BD), amicrobial
pustulosis of the folds (APF) and generalized pustular psoriasis. The presentations by pathology
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of the neutrophil-mediated autoinflammatory skin diseases for
which there is genetic and immunological evidence are reported
in Table 1. As PG with its syndromic forms is the prototypical
ND and has a large body of research available, it will be the
focal point of the discussion. Concerning the other entities, since
there are no extensive research data available in the literature,
their links with suggested mechanisms would be speculative.
Each disease may present within an overlapping spectrum both
clinically and histopathologically which can make diagnosis
difficult and management challenging. The central features of
NDs have significant overlap with disorders included within
the spectrum of autoinflammatory conditions which manifest
as reoccurring periods of tissue inflammation (18). However,
in contrast to appropriate inflammatory responses to insults
TABLE 1 | Clinical, genetic, and immunological features of the main autoinflammatory neutrophil-mediated skin diseases.
Disease Cutaneous presentation Genetics Immunology References
PG Ulcers with undermined,
erythematous-violaceous
borders
MEFV, NLRP3, NLRP12, NOD2, and LPIN2
mutations
Increased skin IL1β, IL1RI, IL1RII, TNFβ, TNFRI,
TNFRII, IL17, IL17R, L-selectin, IL8, CXCL
1/2/3, CXCL16, RANTES, MMP-2, MMP-9,
TIMP-1, TIMP-2, Siglec 5, Siglec 9, Fas, FasL,
CD40, and CD40L
(1, 2)
R52Q mutation in the PSTPIP1 gene Not evaluated (3)
G258A and R52Q mutations in the PSTPIP1
gene
Not evaluated (4)
Not evaluated Increased skin IL23 (5)
Ptpn6 mutations Increased serum IL1α (6–8)
PAPA Ulcers with undermined,
erythematous-violaceous
borders; inflammatory acne
E250K in the PSTPIP1 gene Increased serum IL1β (9)
E250Q and A230T mutations in the PSTPIP1
gene
Not evaluated (10)
PASH Ulcers with undermined,
erythematous-violaceous
borders; nodules, abscesses,
fistulae
p.I591T, p.M694V, p.V726A mutations in the
MEFV gene; p.R702W and p.G908R in the
NOD2 gene; p.Q703K in the NLRP3 gene;
p.A106T in the IL1RN gene; p.E277D in the
PSTPIP1 gene; and p.G8R in the PSMB8 gene
Increased skin IL1β, IL1RI, IL1RII, TNFα,
TNFRI, TNFRII, IL-17, IL17R, L-selectin, IL-8,
CXCL1/2/3, CXCL16, RANTES, MMP-2,
MMP-9, TIMP-1, TIMP-2, Siglec 5, Siglec 9,
Fas, FasL, CD40, and CD40L
(1)
Increased CCTG microsatellite repeats in the
PSTPIP1 gene
Not evaluated (11)
MEFV, NLRP3, NLRP12, NOD2, and LPIN2
mutations
IL-1-b, IL-17, TNFα, IL-8, CXCL1/2/3, and
CXCL16
(2)
PAPASH Ulcers with undermined,
erythematous-violaceous
borders; nodules, abscesses,
fistulae
p.E277D missense mutation in the PSTPIP1
gene
Not evaluated (12)
DIRA Generalized pustular psoriasis Monogenic (IL1RN mutations) Increased serum IL1α, macrophage
inflammatory protein 1α, TNFα, IL8, and IL6
(13)
DITRA Generalized pustular psoriasis Monogenic (IL36RN mutations) Increased keratinocyte production of IL8 in
response to proinflammatory cytokines (IL36α,
IL36β, and IL36γ) as well as to IL1β and
polyinosinic–polycytidylic acid
(14, 15)
CAPS Urticaria-like lesions Monogenic (NLRP3 mutations) Increased serum IL1β and IL18 (16, 17)
CAPS, Cryopyrin-Associated Periodic Syndromes; CD40, cluster of differentiation 40; CD40, CD40 ligand; CXCL, chemokine (C-X-C motif) ligand; DIRA, Deficiency of IL-1 receptor
antagonist; DITRA, Deficiency of IL-36 receptor antagonist; E-selectin, endothelial selectin; IL, interleukin; IL1RN, interleukin-1 receptor antagonist; IL-xR, interleukin-x receptor; LPIN2,
Lipin 2; L-selectin, leukocyte selectin; MEFV, Mediterranean fever; MMP, matrix metalloproteinase; NLRP, nucleotide-binding domain, leucine-rich repeat containing gene family, pyrin
domain-containing protein; NOD2, Nucleotide-binding oligomerization domain-containing protein 2; PAPA, Pyogenic sterile arthritis, Pyoderma Gangrenosum, and acne; PAPASH,
Pyogenic sterile arthritis, PG, and acne; PASH, Pyoderma Gangrenosum, Acne and Suppurative Hidradenitis; PG, Pyoderma Gangrenosum; PSMB8, proteasome subunit beta
8; PSTPIP1, proline–serine–threonine phosphatase interactive protein 1; RANTES, Regulated upon Activation, Normal T cell Expressed, and Secreted; Siglec, Sialic acid-binding
immunoglobulin-type lectins; TIMP, Tissue inhibitor of metalloproteinases; TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor; VEGF, vascular endothelial growth factor.
or to autoimmune disease, there is an absence of identifiable
pathogens, autoantibodies, or autoreactive lymphocytes (16).
The concept of autoinflammation arose out of the discovery of
conditions resulting from specific genetic mutations leading to
chronic inflammation devoid of autoreactive T cells (or antigen
specific T cells) or autoantibodies. The first autoinflammatory
disease identified, TNF (tumor necrosis factor) receptor-
associated periodic syndrome (TRAPS), was described in
1999 upon identification of TNF receptor mutations in the
autosomal dominant condition (19). Dysregulation of innate
immunity signaling pathways particularly the overexpression of
the proinflammatory cytokine interleukin (IL)-1, is considered
to be the prominent mechanism behind the pathophysiology of
these disorders (20).
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MECHANISMS OF INFLAMMATION IN
NEUTROPHILIC DERMATOSES
Insights From Inherited Autoinflammatory
Syndromes
The recognition of several monogenic diseases which can
present with ND has led to an improved understanding of
the possible mechanisms of polygenic non-mendelian inherited
ND. These monogenic syndromes include CAPS (Cryopyrin-
Associated Periodic Syndromes), DIRA [Deficiency of IL-1
receptor antagonist (IL-1RA)], DITRA [Deficiency of IL-36
receptor antagonist (IL-36RA)], PAPA (Pyogenic sterile arthritis,
PG, and acne), and chronic recurrent multifocal osteomyelitis
(CRMO) (21, 22).
CAPS are a group of rare inherited inflammatory disorders
associated with dominant mutations in the cryopyrin-coding
gene NLRP3 (nucleotide-binding domain, leucine-rich repeat
containing gene family, pyrin domain-containing protein 3) on
chromosome 1q44 which is also known as CIAS1, PYPAF1, or
NALP3. Currently, more than 90 mutations involving NLRP3
and associated with CAPS phenotypes have been reported.
CAPS contain a spectrum of hereditary periodic fever
syndromes including familial cold autoinflammatory syndrome
(FCAS), Muckle-Wells Syndrome (MWS), and chronic infantile
neurological cutaneous and articular syndrome (CINCA),
also known as neonatal-onset multisystem inflammatory
disease (NOMID). Characteristic symptoms are periodic
fever and urticarial lesions. Dependent on severity, they can
be associated with several clinical manifestations, including
arthritis, conjunctivitis, amyloidosis, sensorineural hearing loss,
aseptic meningitis, and/or cerebral atrophy (17).
DIRA is an autosomal recessive mutation in IL1RN (IL-
1RA gene) on chromosome 2 leading to the absence of IL-
1RA, resulting in an IL-1 signaling hyperactivity (13, 23). DIRA
manifest as perinatal-onset pustular dermatitis, joint swelling,
painful osteolytic lesions, and periostitis.
DITRA is caused by homozygous or compound heterozygous
damaging mutations in IL36RN and is characterized by
generalized pustular rashes and systemic inflammation (14, 15).
IL36RN encodes for IL-36RA which inhibits binding of IL-36
to its receptor. When IL36RA is functionally impaired there
is an enhanced IL-36R signaling which directly and indirectly
attracts immune cells, especially neutrophils, giving rise to
the pustular rashes (14, 15). IL-36 has been reported to be
upregulated in a psoriasis-like inflammatory mouse model (24),
confirming the role of this cytokine family in the pathogenesis of
pustular psoriasis (25). Moreover, a strong correlation has been
demonstrated in human psoriatic skin between the expression
of IL-36 and that of other cytokines, such as IL-17, IL-
23, TNF-α, and IFN-γ (26), suggesting that a positive gene
expression loop might occur in psoriasis. Moreover, IL-36 also
enhances IL-1α levels, further amplifying the inflammatory
network (27). Thus, the IL-1/IL-36 inflammatory axis appears
to be a key player of disease pathology in generalized pustular
psoriasis (28) and its role may be intriguingly hypothesized
also in other NDs, although it needs to be confirmed by
dedicated studies.
PAPA syndrome is due to two primary mutations (A230T
and E250Q) in the gene encoding proline–serine–threonine
phosphatase interactive protein 1 (PSTPIP1) (10, 29).
Hyperphosphorylation of the mutated PSTPIP1 protein results
in increased pyrin mediated activation of the inflammasome,
dysregulation of caspase 1, and overexpression of IL-1β (29).
The presence of a prototypical ND such as PG in the context
of PAPA syndrome, caused by a single inflammasome regulator
gene mutation, suggests an autoinflammatory component
in the pathophysiology of NDs (30). The occurrence of
mutations in a single gene encoding an inflammasome regulating
protein, as seen in PAPA, is similar to what happens in the
first monogenic autoinflammatory conditions identified, i.e.,
familial Mediterranean fever and CAPS. Yet further studies have
identified autoinflammatory syndromes with features of ND
that are linked to mutations in multiple genes. In addition to
PAPA, PG can present with other autoinflammatory syndromes
including PG, acne, and suppurative hidradenitis (PASH) and
pyogenic arthritis, PG, acne, and suppurative hidradenitis
(PAPASH). The findings of these syndromic forms of PG along
with reports of familial presentations of PG suggest the shared
genetic basis of this ND (1, 11, 12, 31, 32).
Investigation of 7 cases of PASH and 13 cases of isolated PG
revealed multiple mutations in a variety of autoinflammatory
genes, including PSTPIP1, Mediterranean fever (MEFV),
Nucleotide-binding oligomerization domain-containing protein
2 (NOD2), NLRP3, NLRP12, Lipin 2 (LPIN2) (2). The MEFV
gene encodes for the protein pyrin, which is an innate immune
system sensor which plays a central role in inflammasome
activation. Different mutations in the genetic sequence can lead
to variable clinical presentations with overlapping features.
In NDs, MEFV (S242R) mutations have been identified and
lead to a chronically active pathogen-related response with
inflammasome activation and IL-1β secretion (33). NOD2 is
an intracellular pattern recognition receptors (PRRs) that plays
a key role in orchestrating the proper assembly of autophagy-
related proteins. Autophagy involves a cellular response resulting
in the degradation of cytoplasmic components and is important
in the transfer of microbial components to intracellular PRRs.
The catabolic autophagy pathway responds to a wide variety
of cellular stressors including nutrient deprivation, hypoxia,
DNA damage, mechanical injury, reactive oxygen species (ROS),
and the presence of microbial ligands (34). Loss of function
mutations in NOD2 result in impaired autophagy and have been
associated with inflammatory bowel disease (IBD), a condition
characterized by heightened production of proinflammatory
cytokines and often associated with ND comorbidity (35).
Autophagy has been shown to be important in mitochondrial
homeostasis (36) and its deficiency is associated with increased
mitochondrial membrane permeability and ROS production, and
the release of mitochondrial DNA into the cytosol (36–38).
Mitochondrial DNA and ROS are both activators of the NLRP3
inflammasome (36, 37). Studies have revealed that macrophages
with defective autophagy have decreased NLRP3 inflammasome
activation (38). We speculate that mutations in NOD2 lead to
defective autophagy causing increased production of ROS and
the release of mitochondrial DNA resulting in NLRP3 activation
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and subsequent ND. These findings point to the polygenic basis
of NDs and helped establish the categorization of NDs among
the autoinflammatory disorders. The polygenic nature suggests
that NDs arise from a multifactorial response in genetically
predisposed patients.
Neutrophil Production and Recruitment
In normal physiology, neutrophils are heralded as major effector
cells in acute inflammation. As the most abundant leukocytes
in circulation, neutrophils have been extensively described
as protagonists against infection and innate immune system
responders to insults. Within the bone marrow, the production
and differentiation of neutrophils is regulated primarily by
granulocyte colony-stimulating factor (G-CSF) (39). G-CSF also
acts to promote release of mature neutrophils from the bone
marrow into circulation. This is accomplished by the uncoupling
of the CXC-chemokine receptor 4 (CXCR4) and CXC-chemokine
ligand 12 (CXCL12) (39).
Within tissues, the “neutrostat” loop is a feedback pathway
which normally suppresses neutrophilic response by suppressing
production of G-CSF. This loop is initiated after phagocytosis
of infiltrative neutrophils, resulting in suppression of IL-23
production by resident macrophages and dendritic cells and
subsequent decreased secretion of IL-17, an important promoter
of G-CSF production (40–42). Evaluation of patients with NDs
has shown significantly elevated serum G-CSF, and therapeutic
G-CSF is implicated in a majority of drug-induced SS cases,
indicating a plausible but undiscovered contributing mechanism
underlying ND (43–47). In addition, elevated IL-17 levels have
been found in tissue samples from patients with PG, SS, and APF,
a rare ND presenting with pustular lesions typically involving the
skin folds and anogenital area (48–52). IL-17 is a key cytokine
in both activation and induction of neutrophils to produce IL-
8, a potent chemokine that is the principle chemoattractant of
neutrophils. Increased levels of IL-8 have been found in ND
lesional skin, and the chemokine works synergistically with TNF-
α to potentiate and maintain a proinflammatory state (1, 2, 16,
18–21, 49, 50, 53). In mice models, experiments have revealed
that protein kinase C α (PKCα) within keratinocytes promotes
neutrophil infiltration of the epidermis, and may also play a
central role in upregulation of G-CSF and IL-6 gene expression
independent of TNF-α signaling, giving the possibility of a
peripheral mechanism of ND (54).
Innate Immune System Activation
The innate immune system uses germline encoded PRRs to
recognize pathogen-associated molecular patterns (PAMPs),
including (foreign) PAMPs and (endogenous) damage-associated
molecular patterns (DAMPs), to initiate the production of
proinflammatory cytokines (55). Changes in local cellular
homeostasis including temperature, pH, oxygen, and osmolarity
are recognized as DAMPs by resident tissue macrophages
(55). Recognition of DAMPs initiates an inflammatory cascade
involving the inflammasome which consists of a central
scaffold of proteins, a sensor (including Nod-like Receptors),
the adaptor protein ASC [apoptosis associated speck-like
protein containing a caspase-associated recruitment domain
(CARD)] and the effector protein caspase-1 (22). Members
of the NLRP (Nucleotide-binding oligomerization domain,
Leucine-rich Repeat and Pyrin domain-containing) family, are
the primary cytoplasmic PRRs that mediate inflammasome
activation (55). Oligomerization of the inflammasome results in
caspase-1 activation leading to the cleavage of pro-IL-1β and pro-
IL-18 to IL-1β and IL-18 (22, 55). Gain-of-function mutations in
NLRP3 gene are responsible for the development of autosomal
dominant inflammatory disorders which typically presents with
episodic urticarial neutrophil-rich cutaneous lesions, known
as CAPS (see above) (56). Although NLRP3 mutations are
prototypically responsible for inflammasome activation, other
mutations such as those involving IL-1 and IL-36 pathway
genes may also induce inflammasome activation (13, 14). The
symptoms of CAPS are the result of overexpression of IL-
1β secondary to constitutive activation of the cytoplasmic
macromolecular complex. Evaluation of patients with ND
have also shown elevated serum and lesional tissues IL-
β levels (50, 57, 58). In addition, keratinocytes exposed to
ultraviolet B irradiation, contact allergens or in the setting
of psoriasis activate similar inflammasome pathways resulting
in IL-1β production and subsequent neutrophil localization
and activation (59–61), although there is support from mouse
models that bone marrow-derived cells with isolated NLRP3
mutations are sufficient to induce IL-1β associated cutaneous
autoinflammation (62).
Immune Signal Transduction
Immune cell proinflammatory signal transduction is inhibited
by the tyrosine phosphatase known as Src homology region
2 (SH2) domain–containing phosphatase-1 (SHP-1) (63, 64).
Dysfunctional activity of SHP-1 is associated with various
diseases including multiple sclerosis, leukemia and psoriatic
arthritis (65–69). SHP-1, also known as PTPN6 (protein tyrosine
phosphatase nonreceptor type 6), is encoded by the gene Ptpn6.
Heterozygous mutations and splice variants of Ptpn6 have been
identified in patients with PG and SS (4).
Ptpn6spin mice are the product of a Y208N (or Tyr208Asn)
missense mutation leading to amino acid substitution in the
carboxy-terminal SH2 domain of SHP-1. These mice develop
severe cutaneous inflammation driven by overexpression of
IL-1α (6). Histopathologically, the inflammatory cutaneous
lesions resemble human NDs, with neutrophil-rich infiltrate
and pustules within the epidermis, and are associated with
neutrophilia. These data may support the role of mutations
involving Ptpn6 in triggering NDs in humans.
The Kanneganti group have utilized this murine model to
characterize key regulatory components of neutrophil-mediated
cutaneous autoinflammation. These authors have surprisingly
shown that IL-1α signaling, but not IL-1β or caspase-1 associated
inflammasome, plays a key role in orchestrating cutaneous
autoinflammation in Ptpn6spin mice (6). Their work has
elucidated the complex regulation of the IL-1α pathway and
identified a number of signaling components as pivotal in
the development of cutaneous inflammation in Ptpn6spin mice,
such as IL-1 receptor (IL-1R), myeloid differentiation primary
response gene 88 (MyD88) (7), spleen tyrosine kinase (Syk)
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FIGURE 1 | Model of IL-1α (Interleukin 1α)-mediated autoinflammation in
neutrophilic dermatoses. In normal physiologic conditions SHP-1 (Src
homology region 2 domain-containing phosphatase-1) acts to inhibit Syk
(spleen tyrosine kinase) which subsequently downregulates the activation of
IL-1R and Dectin-2 proinflammatory pathways. Dysfunction in SHP-1 leads to
uncoupled Syk activity, subsequently leading to a neutrophil-driven
autoinflammatory state via an exaggerated release of proinflammatory
cytokines and other effector molecules. Bcl10, B-cell lymphoma/leukemia 10;
CARD9, Caspase recruitment domain-containing protein 9; FcRy, Fc receptor
common γ chain; G-CSF, Granulocyte Colony Stimulating Factor; IL-1R,
Interleukin 1 receptor; MALT-1, Mucosa-associated lymphoid tissue lymphoma
translocation protein 1; MyD88, Myeloid differentiation primary response 88;
RIPK1, Receptor-interacting serine/threonine-protein kinase 1; TAK1,
Transforming growth factor beta-activated kinase 1; TNF-α, Tumor necrosis
factor α.
(7), receptor interacting protein kinase 1 (RIPK1) (6), tumor
growth factor-β activated kinase 1 (TAK1) (7) and apoptosis
signal-regulating kinase 1 (ASK1) (8).
SHP-1 was also shown to regulate IL-1α signaling primarily
through preventing phosphorylation of MyD88 by Syk (7). This
pathway is illustrated in Figure 1. Of note, the Kanneganti group
showed that inflammation in Ptpn6spin mice is independent of
toll-like receptors (TLRs), IFN-α/β receptor (IFNAR), integrin
β-3 (ITGB3), NOD2–RIPK2 signaling, and independent of
stimulator of IFN genes (STING) (7, 70). Support for unique role
of IL-1α signaling in the development of cutaneous inflammation
in Ptpn6spin mice is strengthened by ruling out the influence of
these additional innate immune signaling pathways (7, 70).
Recently, CARD9 signal transduction was identified as an
essential mediator of cutaneous inflammation in Ptpn6spin
mice (71).
CARD9 is an adapter protein downstream of Syk and is central
transducer for multiple innate signaling pathways including
the C type lectin receptors, Dectin-1 and Mincle pathways
(72). CARD9 forms a complex with MALT1 (mucosa-associated
lymphoid tissue lymphoma translocation protein 1) and BCL10
(B-cell lymphoma/leukemia 10) leading to initiation of the
NF-κB (nuclear factor kappa-light-chain-enhancer of activated
B cells) signaling cascade and increased transcription of pro-
inflammatory cytokines (TNF and IL-6) resulting in T helper
(Th)17 polarization (73).
As previously discussed, IL-17 is a key signaling molecule in
ND pathogenesis. CARD9 is thus linked to cytokine production,
innate anti-fungal immunity, and myeloid cell activation (72).
Identification of the key role of CARD9 in the autoinflammatory
signaling pathway suggests the interconnection between NDs
and other autoinflammatory conditions. Interestingly, CARD9
mutations are associated with IBD (74) and deletion in
CARD9 significantly dampens the IL1-mediated cutaneous
inflammatory disease in a mouse model knockout for CARD9
(70). Aberrant signaling involving SHP-1, Syk, and CARD9
can lead to neutrophil-mediated autoinflammation driven by
overproduction of IL-1α. Thus, blocking these signals may
provide a novel approach to design effective therapeutic strategies
to treat NDs.
PATHOGENESIS-DRIVEN TREATMENT OF
NEUTROPHILIC DERMATOSES
Several lines of evidence indicate that IL-1 blockers, namely
anakinra, rilonacept, gevokizumab, and canakinumab, are
effective in the treatment of skin manifestations of different
autoinflammatory disorders. The introduction of these
pharmacological agents represents a breakthrough not only
in the management of monogenic inherited autoinflammatory
diseases but also of skin diseases where neutrophils play a
crucial pathogenic role. More specifically, Brenner et al. (75)
reported complete healing of PG and acne in a patient affected
by PAPA after 1 month-therapy with anakinra 100 mg/day.
Similarly, canakinumab 150mg every 8 weeks led to complete
remission of PG and acne lesions in another PAPA patient.
Two case reports are present in the literature on two patients
with PASH treated with anakinra, who both experienced a
partial remission of skin lesions (11, 76). In an open-label,
proof of concept study conducted on six patients with active
PG who were given three subcutaneous injections once every
4 weeks of the anti-IL-1β monoclonal antibody gevokizumab,
complete remission of PG was observed in four patients, a
partial response in one patient and another one did not respond.
(ClinicalTrials.gov Identifier: NCT01882504) Conversely, a
phase 3 trial demonstrated limited effectiveness of the same drug
on PG patients. (ClinicalTrials.gov Identifier: NCT02326740
and NCT02315417) Complete PG clearance under canakinumab
treatment has been described in two patients after 3 (77)
and 12 months (78), respectively. Canakinumab effectiveness
has also been assessed in an open-label study on five PG
patients unresponsive to systemic steroids, with three out
of five achieving complete remission at 16-week follow-up
visit (79). A prompt and long-lasting response to anakinra
in terms of both cutaneous and systemic manifestations has
been described in a patient with SS (80). In another SS patient,
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Kluger et al. observed that, despite a relatively rapid response
to anakinra, both skin and systemic symptoms relapsed upon
drug withdrawal (81). Amazan et al. reported on a woman
with steroid- and anti-TNFα- refractory APF who experienced
complete healing of her lesions on a regimen of 100 mg/day
anakinra (82).
A rapid and robust clinical response to secukinumab,
an anti-IL-17 monoclonal antibody, was reported in an
adolescent with severe cutaneous manifestations due to
DITRA (83). In addition to the latter clinical observation, a
pathomechanistic link between IL-36 and Th17 differentiation
may be postulated also based on the findings by Carrier
et al. (26), who showed a direct correlation between IL-
36 gene expression and IL-17 levels in the lesional skin of
psoriatic patients.
Future perspectives in the management of PG involve the IL-
1α blockade. IL-1α overproduction has been demonstrated
in response to deregulated SHP-1 activity triggering a
severe neutrophil-mediated inflammatory disease that
develops independently of inflammasome. Based on these
findings, there is an ongoing phase 2 open-label trial using
bermekimab, an IL-1α inhibitor, in PG (ClinicalTrials.gov
Identifier: NCT01965613).
CONCLUSIONS
NDs are a complex, variable and heterogenous group of
diseases which have significant overlap in presentation and
pathogenesis. Our understanding of the molecular mechanisms
of NDs is based primarily on the discovery of familial variants,
classification of autoinflammatory syndromes and development
of mouse models. While understanding of disease mechanisms
has not yet been completely elucidated, NDs are recognized
as a polygenic multifactorial disease process which involves
dysfunctional cellular signaling mediated by pathways mainly
related to inflammasome and IL-1 with the contributory role of
IL-17 and other effector molecules. The precise elucidation of the
above-mentioned pathologic mechanisms will pave the way to
tailored treatments for patients with different NDs.
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